This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Sat May 18, 2013 3:26 pm

View unanswered posts | View active topics


Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]



Post new topic Reply to topic  Page 1 of 1
  [ 6 posts ] 
  Print view Previous topic | Next topic 
Author Message
CureOrBust
PostPosted: Wed Oct 01, 2008 6:00 am 
Online
Family Elder
User avatar

Joined: Wed Jul 27, 2005 3:00 pm
Posts: 2684
Location: Sydney, Australia
Quote:
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)[Outline] ... SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with AL...RICHMOND Calif. Sept. 3 /- SangamoBioScience...Sangamo's drug SB-509 is an injectable formulation of a plasmidenco...

emailDate:9/3/2008

SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with ALS

RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure.

Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). SB-509 is also in three additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown to have nerve protection properties as well as promoting nerve, blood vessel and muscle growth.

Full Article Here
Top
 Profile  
 
gibbledygook
 Post subject:
PostPosted: Wed Oct 01, 2008 10:37 am 
Offline
Family Elder
User avatar

Joined: Mon Feb 14, 2005 4:00 pm
Posts: 1363
Location: London
this is interesting. I believe that vascular endothelial growth factor (VEGF) is upregulated in MS especially during relapse and that it may contribute to blood brain barrier permeability. Odd that they wish to upregulate it. I'm looking for herbs that inhibit it!

_________________
3 years antibiotics, 06/09 bilateral jug stents at C1, 05/11 ballooning of both jug valves, 07/12 stenting of renal vein, azygos & jug valve ballooning,
Top
 Profile  
 
CureOrBust
 Post subject:
PostPosted: Thu Oct 02, 2008 3:18 am 
Online
Family Elder
User avatar

Joined: Wed Jul 27, 2005 3:00 pm
Posts: 2684
Location: Sydney, Australia
gibbledygook wrote:
Odd that they wish to upregulate it.
If it does increase nerve protection and growth, not so unexpected.
gibbledygook wrote:
it may contribute to blood brain barrier permeability.
Well it is for ALS, I am guessing that ALS isn't as driven by BBB permeability as MS is.

If you are trying to down-regulate it, maybe you should be concerned that you will also be missing out on the protection and growth properties.
Top
 Profile  
 
gibbledygook
 Post subject: Gingko biloba
PostPosted: Thu Oct 16, 2008 6:15 am 
Offline
Family Elder
User avatar

Joined: Mon Feb 14, 2005 4:00 pm
Posts: 1363
Location: London
Wow, well gingko biloba, a known inhibitor of VEGF is proving a marvel at reducing the tingles. It's early days but I reckon this herb is THE way, even better than salvia. It has vasodilatory and axonal repair characteristics too. I now think that trying to upregulate VEGF is crazy and wouldn't go into the trial if they paid me a trillion dollars.

_________________
3 years antibiotics, 06/09 bilateral jug stents at C1, 05/11 ballooning of both jug valves, 07/12 stenting of renal vein, azygos & jug valve ballooning,
Top
 Profile  
 
CureOrBust
 Post subject: Re: Gingko biloba
PostPosted: Fri Oct 17, 2008 12:46 am 
Online
Family Elder
User avatar

Joined: Wed Jul 27, 2005 3:00 pm
Posts: 2684
Location: Sydney, Australia
gibbledygook wrote:
I now think that trying to upregulate VEGF is crazy and wouldn't go into the trial if they paid me a trillion dollars.
See, I think its CRAZY not to accept a trillion dollars (and be non-comliant)
Top
 Profile  
 
gibbledygook
 Post subject:
PostPosted: Fri Oct 17, 2008 1:13 am 
Offline
Family Elder
User avatar

Joined: Mon Feb 14, 2005 4:00 pm
Posts: 1363
Location: London
Ah yes, well I could just be totally dishonest, accept the trillion dollars and not take whatever drug it is and stick to the ginkgo but that thought never passed my innocent little brain!!

I'm glad that they are focusing on VEGF, after all it this which causes vascular permeability and is implicated in tumorgenesis. Can't for the life of me understand why they want to upregulate it though.

Didn't have a single spasm last night after 4.8g of gingko plus 3.6g salvia plus curcumin plus scutellaria. Legs feel much stronger, a bit stiff but hardly a tingle anywhere. On the whole I feel that the gingko is stopping blood from leaking into the CNS, the salvia makes the vasculature less constricted and that that is all we really need to worry about. I reckon most of the inflammation is caused by blood getting into tissue it doesn't normally touch. If you heal up the vasculature then you'll recover. Next drugs to experiment on are horsechestnut and hesperidin for even greater vascular health. :lol:

_________________
3 years antibiotics, 06/09 bilateral jug stents at C1, 05/11 ballooning of both jug valves, 07/12 stenting of renal vein, azygos & jug valve ballooning,
Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  Page 1 of 1
  [ 6 posts ] 

Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]

Who is online

Users browsing this forum: No registered users

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to: